European Pharmaceutical Review
FEBRUARY 27, 2024
Novel biosimilar approval In the same month, the US Food and Drug Administration (FDA) approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference blockbuster drug Stelara (ustekinumab). The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.
Pharmaceutical Technology
JUNE 7, 2023
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. A decision from the FDA is possible for later this year, with Lilly currently finalizing an application for fast-track approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 22, 2022
The pharmaceutical company is well on its way to achieving its goals with successful full reimbursements, already confirmed in the United Kingdom ( UK), and Sweden. GlobalData is the parent company of Pharmaceutical Technology. Following this, in 2019, the FDA approved Vazkepa for the reduction of cardiovascular risk.
European Pharmaceutical Review
AUGUST 1, 2022
The DDiCT initiative aligns with the pharmaceutical company’s broader diversity and inclusion goals for 2020-2025, which aim to address health disparities, clinical trial diversity, supplier diversity, employee giving and workforce representation. Efforts to improve clinical trial diversity are ongoing.
European Pharmaceutical Review
MARCH 7, 2024
Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?
The Checkup by Singlecare
OCTOBER 27, 2023
How to get Vyzulta without insurance Vyzulta is a brand-name prescription eye drop medication that is approved by the Food and Drug Administration (FDA) to reduce eye pressure in people with open-angle glaucoma or high eye pressure. The earliest date that a generic version could be available is in 2025. Is Vyzulta covered by insurance?
PharmaShots
MAY 23, 2023
Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. The company first received the US FDA approval for its gene therapy Zynteglo in Aug 2022 for treating adult and pediatric patients with ß-thalassemia. Total Revenue: $1.9B
Expert insights. Personalized for you.
95 
Let's personalize your content